DK2531518T3 - Oligopeptidforbindelser og anvendelser deraf - Google Patents

Oligopeptidforbindelser og anvendelser deraf Download PDF

Info

Publication number
DK2531518T3
DK2531518T3 DK11701678.2T DK11701678T DK2531518T3 DK 2531518 T3 DK2531518 T3 DK 2531518T3 DK 11701678 T DK11701678 T DK 11701678T DK 2531518 T3 DK2531518 T3 DK 2531518T3
Authority
DK
Denmark
Prior art keywords
cancer
compound
cell
peptide
cells
Prior art date
Application number
DK11701678.2T
Other languages
English (en)
Inventor
Lars Prestegarden
Original Assignee
Cytovation As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cytovation As filed Critical Cytovation As
Application granted granted Critical
Publication of DK2531518T3 publication Critical patent/DK2531518T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C07K14/08—RNA viruses
    • C07K14/15—Retroviridae, e.g. bovine leukaemia virus, feline leukaemia virus human T-cell leukaemia-lymphoma virus
    • C07K14/155—Lentiviridae, e.g. human immunodeficiency virus [HIV], visna-maedi virus or equine infectious anaemia virus
    • C07K14/16—HIV-1 ; HIV-2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702—Regulators; Modulating activity
    • C07K14/4703—Inhibitors; Suppressors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Zoology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Virology (AREA)
  • Toxicology (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • AIDS & HIV (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Hematology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Claims (15)

1. Oligopeptidforbindelse omfattende: (i) aminosyresekvensen af YGRKKRRQRRRGKTLRVAKAIYKRYIE (SEQ ID NO: 40); eller (ii) en aminosyresekvens med mindst 85% sekvensidentitet til sekvensen af SEQ ID NO: 40; hvor forbindelsen af (i) eller (ii) har aktivitet i inhibering af væksten og/eller levedygtigheden af mikrobielle og cancerceller, hvor fortrinsvis oligopeptidforbindelsen har sekvensen af SEQ ID NO: 40.
2. Oligopeptidforbindelse ifølge krav 1, hvor forbindelsen omfatter en eller flere D-aminosyrer, hvor fortrinsvis forbindelsen er en inverso-forbindelse som indeholder alle D-aminosyrer.
3. Oligopeptidforbindelse ifølge et hvilket som helst af kravene 1 eller 2, hvor forbindelsen har en eller flere af de følgende egenskaber: a) en netto-ladning ved pH 7,0 på 10-13, b) en pi på 12 til 13; c) en gennemsnitlig hydrofilicitet på 0,7 til 1,0 og/eller d) et forhold mellem hydrofile rester og total antal af rester på 45-60%.
4. Oligopeptidforbindelse ifølge et hvilket som helst af kravene 1 til 3, hvor forbindelsen er antibakteriel og cytotoksisk.
5. Oligopeptidforbindelse ifølge et hvilket som helst af kravene 1 til 4, som er selektivt cytotoksisk mod cancerceller, og/eller hvor forbindelsen kan mindske tumorstørrelse.
6. Nukleinsyremolekyle som koder for en aminosyresekvens som defineret i et hvilket som helst af kravene 1 eller 2, eller komplementet af nukleinsyremolekylet.
7. Vektor omfattende et nukleinsyremolekyle ifølge krav 6.
8. Isoleret celle som er blevet modificeret ved introduktionen af et nukleinsyremolekyle eller en vektor ifølge krav 6 eller 7.
9. Farmaceutisk sammensætning omfattende en oligopeptidforbindelse eller et nukleinsyremolekyle ifølge et hvilket som helst af kravene 1 til 7 sammen med en farmaceutisk acceptabel excipiens.
10. Oligopeptidforbindelse, nukleinsyremolekyle eller sammensætning ifølge et hvilket som helst af kravene 1 til 9 til anvendelse i terapi, fortrinsvis til anvendelse i bekæmpelse af mikrobiel infektion eller til anvendelse i behandlingen af cancer; hvor når anvendt i behandlingen af cancer, da er canceren fortrinsvis valgt fra hjerne-, lunge-, bryst- eller tyktarmscancer eller melanom og/eller hvor oligopeptidforbindelsen, nukleinsyremolekylet, sammensætningen eller medikamentet er til lokal levering til canceren; eller hvor når anvendt til at bekæmpe mikrobiel infektion, da er den mikrobielle infektion fortrinsvis en bakterieinfektion.
11. Anvendelse af oligopeptidforbindelsen eller nukleinsyremolekylet ifølge et hvilket som helst af kravene 1 til 9 i fremstillingen af et medikament til at bekæmpe mikrobiel infektion og/eller at behandle cancer.
12. Produkt omfattende en oligopeptidforbindelse, et nukleinsyremolekyle eller en sammensætning ifølge et hvilket som helst af kravene 1 til 9 og et andet terapeutisk aktivt stof som et kombineret præparat til separat, samtidig eller sekventiel anvendelse i inhibering af levedygtigheden og/eller væksten afen cancer eller mikrobecelle.
13. Kit omfattende en oligopeptidforbindelse, et nukleinsyremolekyle eller en sammensætning ifølge et hvilket som helst af kravene 1 til 9 og et andet terapeutisk aktivt stof.
14. Kit eller produkt ifølge krav 12 eller 13 hvor det andet terapeutisk aktive stof er aktivt mod cancer eller mikrobiel infektion eller cancer, og/eller hvor det andet terapeutisk aktive stof er et kemoterapeutisk stof, et anti-neoplastisk stof, et antibiotika, eller et antiviralt eller svampedræbende stof.
15. In vitro eller ex vivo fremgangsmåde til inhibering af levedygtigheden og/eller væksten afen mikroorganisme eller cancercelle, hvor fremgangsmåden omfatter at bringe mikroorganismen i kontakt med en oligopeptidforbindelse, eller at bringe cancercellen i kontakt med en oligopeptidforbindelse eller et nukleinsyremolekyle, ifølge et hvilket som helst af kravene 1 til 6.
DK11701678.2T 2010-02-01 2011-02-01 Oligopeptidforbindelser og anvendelser deraf DK2531518T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB1001602.0A GB201001602D0 (en) 2010-02-01 2010-02-01 Oligopeptidic compounds and uses therof
PCT/EP2011/051422 WO2011092347A1 (en) 2010-02-01 2011-02-01 Oligopeptidic compounds and uses thereof

Publications (1)

Publication Number Publication Date
DK2531518T3 true DK2531518T3 (da) 2016-08-15

Family

ID=42084276

Family Applications (1)

Application Number Title Priority Date Filing Date
DK11701678.2T DK2531518T3 (da) 2010-02-01 2011-02-01 Oligopeptidforbindelser og anvendelser deraf

Country Status (19)

Country Link
US (2) US8754042B2 (da)
EP (1) EP2531518B1 (da)
JP (1) JP5934654B2 (da)
KR (1) KR101848518B1 (da)
CN (1) CN102781953B (da)
CA (1) CA2788726C (da)
CY (1) CY1117872T1 (da)
DK (1) DK2531518T3 (da)
ES (1) ES2585595T3 (da)
GB (1) GB201001602D0 (da)
HR (1) HRP20160922T1 (da)
HU (1) HUE028094T2 (da)
LT (1) LT2531518T (da)
PL (1) PL2531518T3 (da)
PT (1) PT2531518T (da)
RS (1) RS54992B1 (da)
SI (1) SI2531518T1 (da)
SM (1) SMT201600261B (da)
WO (1) WO2011092347A1 (da)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201001602D0 (en) 2010-02-01 2010-03-17 Cytovation As Oligopeptidic compounds and uses therof
CN103012562B (zh) * 2011-09-24 2015-01-28 复旦大学 一种双重靶向的d构型多肽及其递药系统
US10039777B2 (en) 2012-03-20 2018-08-07 Neuro-Lm Sas Methods and pharmaceutical compositions of the treatment of autistic syndrome disorders
CN103720655B (zh) * 2012-10-11 2016-05-25 上海纳米技术及应用国家工程研究中心有限公司 一种d型多肽介导的靶向脂质体及其制备方法和应用
KR101782634B1 (ko) * 2015-06-29 2017-10-25 주식회사 큐라클 Amigo2와 3-포스포이노시티드-의존 키나아제 1의 결합 억제용 데코이 펩타이드
BR112019019255A2 (pt) * 2017-03-16 2020-04-14 Microsintesis Inc composições e métodos envolvendo moléculas probióticas
CN108314741B (zh) * 2018-03-22 2021-08-03 中国人民解放军第四军医大学 一种肿瘤血管靶向抗癌肽nkl-dota及其制备方法
CN112543595B (zh) * 2018-05-30 2022-11-01 莫尔豪斯医学院 抗微生物组合物，其制备方法和用途
GB201810058D0 (en) * 2018-06-19 2018-08-08 Cytovation As Combination therapy using a peptide
KR102073144B1 (ko) * 2018-12-13 2020-02-04 주식회사 엘베이스 올리고펩티드를 유효성분으로 포함하는 암의 예방 또는 치료용 약학적 조성물
KR102211985B1 (ko) * 2019-05-02 2021-02-05 주식회사 엘베이스 신규한 올리고펩티드 및 이를 유효성분으로 포함하는 암의 예방 또는 치료용 약학적 조성물
CN110408699A (zh) * 2019-07-11 2019-11-05 福建卫生职业技术学院 肠癌肠道菌群标志物及其应用
GB202000167D0 (en) 2020-01-07 2020-02-19 Cytovation As Composition for treatment of neoplastic lesions
CN115044520B (zh) * 2022-08-12 2022-11-15 北京百奥茵诺生物科技有限公司 一株交替单胞菌及使用其生产单葡萄糖醛酸甘草次酸的方法

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3925542A1 (de) 1989-08-02 1990-02-15 Kallos Verlag Und Versand Gmbh Glueckwunschkarte
US5534110A (en) 1993-07-30 1996-07-09 Lam Research Corporation Shadow clamp
US5595756A (en) 1993-12-22 1997-01-21 Inex Pharmaceuticals Corporation Liposomal compositions for enhanced retention of bioactive agents
FR2739621B1 (fr) 1995-10-05 1997-12-05 Centre Nat Rech Scient Peptides utilisables comme vecteurs pour l'adressage intracellulaire de molecules actives
DE19840875A1 (de) * 1997-09-02 1999-05-12 Max Delbrueck Centrum Mittel zur Diagnose und zur Therapie von Tumorerkrankungen
AU1818299A (en) 1997-12-10 1999-06-28 Washington University Anti-pathogen system and methods of use thereof
GB9814527D0 (en) 1998-07-03 1998-09-02 Cyclacel Ltd Delivery system
EP1958961A3 (en) 1998-11-13 2008-09-03 Cyclacel Limited Transport Vectors
FR2849603B1 (fr) 2003-01-07 2006-09-08 Centre Nat Rech Scient Composition pour le transport intracellulaire de macromolecules ou particules biologiques
US7442681B2 (en) * 2004-02-10 2008-10-28 University Of Virginia Patent Foundation Method of inhibiting vascular permeability
CA2666057C (en) * 2006-10-26 2016-10-11 Genentech, Inc. Genetic variations associated with tumors
WO2008051048A2 (en) * 2006-10-27 2008-05-02 Jeong Moon Kim Method and materials for inhibiting a nuclear export of gsk3
GB0803352D0 (en) * 2008-02-22 2008-04-02 Ntnu Technology Transfer As Oligopeptidic compounds and uses thereof
GB201001602D0 (en) 2010-02-01 2010-03-17 Cytovation As Oligopeptidic compounds and uses therof

Also Published As

Publication number Publication date
KR101848518B1 (ko) 2018-04-12
JP2013517787A (ja) 2013-05-20
CA2788726A1 (en) 2011-08-04
GB201001602D0 (en) 2010-03-17
EP2531518A1 (en) 2012-12-12
CA2788726C (en) 2019-04-02
EP2531518B1 (en) 2016-05-04
CN102781953A (zh) 2012-11-14
CY1117872T1 (el) 2017-05-17
KR20120128135A (ko) 2012-11-26
PL2531518T3 (pl) 2017-01-31
JP5934654B2 (ja) 2016-06-15
WO2011092347A1 (en) 2011-08-04
CN102781953B (zh) 2015-02-04
SI2531518T1 (sl) 2016-09-30
HUE028094T2 (en) 2016-11-28
US8754042B2 (en) 2014-06-17
RS54992B1 (sr) 2016-11-30
LT2531518T (lt) 2016-09-26
US20130023461A1 (en) 2013-01-24
US9353156B2 (en) 2016-05-31
US20150038407A1 (en) 2015-02-05
HRP20160922T1 (hr) 2016-10-07
ES2585595T3 (es) 2016-10-06
PT2531518T (pt) 2016-08-12
SMT201600261B (it) 2016-11-10

Similar Documents

Publication Publication Date Title
DK2531518T3 (da) Oligopeptidforbindelser og anvendelser deraf
Lee et al. Conjugation of cell-penetrating peptides to antimicrobial peptides enhances antibacterial activity
Sun et al. Insights into the membrane interaction mechanism and antibacterial properties of chensinin-1b
Kosikowska et al. Antimicrobial peptides (AMPs) as drug candidates: a patent review (2003–2015)
Gennaro et al. Structural features and biological activities of the cathelicidin‐derived antimicrobial peptides
Song et al. Cell selectivity and mechanism of action of antimicrobial model peptides containing peptoid residues
JP6964577B2 (ja) 抗菌性ペプチド及びその使用方法
Castillo et al. Antimicrobial synergy between mRNA targeted peptide nucleic acid and antibiotics in E. coli
Dawson et al. Properties and applications of antimicrobial peptides in biodefense against biological warfare threat agents
Ma et al. Biochemical property and membrane-peptide interactions of de novo antimicrobial peptides designed by helix-forming units
Ciulla et al. Structure–activity relationships of antibacterial peptides
Bhattacharjya NMR structures and interactions of antimicrobial peptides with lipopolysaccharide: connecting structures to functions
Khemaissa et al. Tryptophan, more than just an interfacial amino acid in the membrane activity of cationic cell-penetrating and antimicrobial peptides
Rajasekaran et al. The design of a cell-selective fowlicidin-1-derived peptide with both antimicrobial and anti-inflammatory activities
He et al. Optimized proteolytic resistance motif (DabW)-based U1-2WD: A membrane-induced self-aggregating peptide to trigger bacterial agglutination and death
Mitra et al. Antimicrobial peptides: vestiges of past or modern therapeutics?
Xie et al. Antimicrobial activities and action mechanism studies of transportan 10 and its analogues against multidrug‐resistant bacteria
Dinh et al. De Novo Design and Their Antimicrobial Activity of Stapled Amphipathic Helices of Heptapeptides.
Hu et al. Lysine stapling screening provides stable and low toxic cationic antimicrobial peptides combating multidrug-resistant bacteria in vitro and in vivo
He et al. Boosting stability and therapeutic potential of proteolysis-resistant antimicrobial peptides by end-tagging β-naphthylalanine
Notariale et al. Protamine-like proteins have bactericidal activity. The first evidence in Mytilus galloprovincialis
Song et al. Identification of new dermaseptins with self-assembly tendency: Membrane disruption, biofilm eradication, and infected wound healing efficacy
CA2451310C (en) Antimicrobial peptides
Zhu et al. Cell selectivity and mechanism of action of short antimicrobial peptides designed from the cell‐penetrating peptide Pep‐1
Behera et al. A rationally engineered small antimicrobial peptide with potent antibacterial activity